

ECLS SARS CoV-2 Addendum Form

Extracorporeal Life Support Organization (ELSO)

Please refer to the ELSO Registry Data Definitions for Details

Unique ID: _____

SARS-CoV-2 Co-Morbidity (Select all that apply)

- | | |
|---|--|
| <input type="checkbox"/> Cancer | <input type="checkbox"/> Pregnancy |
| <input type="checkbox"/> Immunocompromised | <input type="checkbox"/> Asthma |
| <input type="checkbox"/> Diabetes | <input type="checkbox"/> Chronic lung disease (excluding asthma) |
| <input type="checkbox"/> Chronic Renal Insufficiency | <input type="checkbox"/> Chronic heart disease |
| <input type="checkbox"/> Obesity (BMI >30 kg/m ²) | <input type="checkbox"/> Frailty (patients >65 years old) |
| <input type="checkbox"/> Hypertension | |

SARS-CoV-2 Co-Infection (Select all that apply)

- | | | | |
|---|--|--|------------------------------------|
| <input type="checkbox"/> Co-viral infection: | <input type="checkbox"/> Confirmed with RT PCR | <input type="checkbox"/> Culture confirmed | <input type="checkbox"/> Suspected |
| <input type="checkbox"/> Bacterial pneumonia: | <input type="checkbox"/> Confirmed with RT PCR | <input type="checkbox"/> Culture confirmed | <input type="checkbox"/> Suspected |
| <input type="checkbox"/> Blood stream infection: | <input type="checkbox"/> Confirmed with RT PCR | <input type="checkbox"/> Culture confirmed | <input type="checkbox"/> Suspected |
| <input type="checkbox"/> Urinary tract infection: | <input type="checkbox"/> Confirmed with RT PCR | <input type="checkbox"/> Culture confirmed | <input type="checkbox"/> Suspected |

Acute Co-Diagnoses (Select all that apply)

- | | |
|--|--|
| <input type="checkbox"/> ARDS | <input type="checkbox"/> Pneumonia |
| <input type="checkbox"/> Septic Shock | <input type="checkbox"/> Myocarditis |
| <input type="checkbox"/> Heart Failure | <input type="checkbox"/> Acute Renal Failure |
| <input type="checkbox"/> Pneumothorax | |

SARS-CoV-2 Pre-Intubation Respiratory Support (Select all that apply)

- BiPAP CPAP High Flow Nasal Cannula

SARS-CoV-2 Renal Replacement Therapy Support

Renal Replacement Therapy Required on ECMO? Yes No

SARS-CoV-2 Immunomodulator Therapies (Select all that apply)

- | | |
|--|---|
| <input type="checkbox"/> Steroids: Systemic Glucocorticosteroids | <input type="checkbox"/> JAK inhibition |
| <input type="checkbox"/> IVIG: Intravenous Immunoglobulin | <input type="checkbox"/> Chloroquine |
| <input type="checkbox"/> Selective cytokine blockade (Anakinra or Tocilizumab) | <input type="checkbox"/> Remdesivir |
| <input type="checkbox"/> Lopinavir/Ritonavir (Kaletra) | <input type="checkbox"/> Aspirin |

SARS-CoV-2 Blood Testing

Day of Intubation: (within 24 hours of intubation Pre or Post)

CRP level: _____ Not measured
Procalcitonin: _____ Not measured

Pre-ECLS Start: (within 24 hours and/or closest to and before ECLS start)

CRP level: _____ Not measured
Procalcitonin: _____ Not measured

SARS-CoV-2 Pre-ECLS Anticoagulation (after hospital admission and before ECLS Initiation)

- None
- Prophylactic Anticoagulation (anticoagulation agents prescribed *without* defined metrics of therapeutic effect)
 - Heparin (continuous infusion)
 - Low-Molecular-Weight Heparin
 - Direct Thrombin Inhibitor (bivalirudin, argatroban, etc.)
 - Novel Oral Anticoagulants (NOAC)
 - Other
- Targeted Treatment Anticoagulation (anticoagulation agents prescribed *with* defined goals of therapeutic effect)
 - Heparin (continuous infusion)
 - Low-Molecular-Weight Heparin
 - Direct Thrombin Inhibitor (bivalirudin, argatroban, etc.)
 - Novel Oral Anticoagulants (NOAC)
 - Other

Multi-System Inflammatory Syndrome in Children - MIS-C

These questions refer to those patients less than 21 years old

SARS-CoV-2 Diagnostic Testing (only applicable for MIS-C patients)

- Active SARS-CoV-2 infection confirmed by PCR
- Prior SARS-CoV-2 infections confirmed by IgG / IgM serology testing
- MIS-C suspected without positive laboratory testing

SARS-CoV-2 Organ System Involvement (only applicable for MIS-C patients)

- Cardiovascular (please select all clinical manifestation that apply):
 - Systolic ventricular dysfunction by echocardiogram (moderate or severe or ejection fraction <50%)
 - Conduction system disturbance
 - Hemodynamically significant arrhythmia
 - Vasomotor dysfunction / vasoplegia
 - Coronary artery ectasia or aneurysm
- Renal
- Respiratory
- Hematological
- Gastrointestinal
- Dermatological
- Neurological